AI assistant
SCI Investor Presentation 2015
52383_rns_2015-09-11_cc7986af-ea45-4aae-b563-49e668b0f445.pdf
Investor Presentation
Open in viewerOpens in your device viewer
SCI PHARMTECH, ING.
簡報
procedure Thainform Forwardterium Leola
All-HescoryList.Count > 0 these Forwardten inn, Enchind in Michon
Xol ardAckion, Enabled a False and r
CLOSE EXOTORIC + Teres, NYL !! Store population Prosentern Mobile which I is coast plasp: Dispatch, var MII Reading at OleVariable r-way
d destoryTodes + 01 MALDE HARGOLYLAST COMME . HAR I dioryLift Delate Office or 97 Highlip Ladas in Ristory List. Add
DES
RicertyTodes is Newtodes: ar brownsteads then hegin
Doctor Course I'm Falue.
Mel Andex ; a UEZ; Ituna, Index02
AE MANDICON - - 1 About
UP J. ftems, Promer (0, U914
員工數Employee:217 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣733佰萬元(NTD 733mn) 營業項目Business: 原料藥API(53.65%) 中間體Intermediate(39.93%) 特用化學品 Custom-made chemicals(6.42%)
公司概況Outline
| Y2014 | Y2015 | |||
|---|---|---|---|---|
| 歐 洲Europe |
42.65% | 35.86% | ||
| 美 洲America |
21.70% | 32.66% | ||
| 亞 洲Asia |
18.18% | 18.75% | ||
| 國 內Taiwan |
16.63% | 9.81% | ||
| 他 others 其 |
0.84% | 2.92% | ||
| 計Total 合 |
100.00% | 100.00% |
SCI PHARMTECH, INC.
| 誉運概況-IS | Unit: K NTD | |||
|---|---|---|---|---|
| 2015 Q1 | 2015 Q2 | 2015.07 | ||
| 營收Sales | 443,065 | 579,644 | 140,235 | |
| 營業成本COGS | (273, 443) | (360, 661) | (89, 914) | |
| 毛利Gross Profit | 169,622 | 218,983 | 50,321 | |
| 毛利率 GP Ratio | 38.3% | 37.8% | 35.9% | |
| 營業費用Operating Expenses | (53,885) | (64, 179) | (16,592) | |
| 營業利益Operating Income | 115,737 | 154,804 | 33,729 | |
| 營業外損益Non-Operating In/Ex | (2,070) | (5, 449) | 7,093 | |
| 税前淨利 Net Profit before Tax | 113,667 | 149,355 | 40,822 | |
| 所得稅Income Tax | (20, 849) | (24, 605) | ||
| 本期淨利Net Profit after Tax | 92,818 | 124,750 |
SCI
產品組合-Products
| Y2012 | % | Y2013 | % | Y2014 | % |
|---|---|---|---|---|---|
| V.A. | 18.66% | PGA | 18.31% | PGA | 17.49% |
| PGA | 16.61% | Di-VaNa | 16.92% | Di-VANa | 10.09% |
| Di-VaNa | 15.97% | S20/38 | 8.39% | LPF.Na | 8.74% |
| PPON | 7.88% | V.A. | 8.23% | S20/38 | 8.25% |
| Pent-2 | 4.78% | LPF.Na | 6.58% | V.A. | 8.15% |
| 5-HMT | 4.33% | PPON | 6.53% | DBS | 4.60% |
| M85 | 3.89% | 5-HMT | 4.51% | 5-HMT | 4.12% |
| DBS | 2.73% | PEB.Na | 3.98% | NaVA | 3.65% |
| M115 | 2.59% | NaVa | 3.34% | Pent-2 | 3.64% |
| M74 | 2.18% | DBS | 2.63% | T115 | 3.33% |
| Total | 79.62% | Total | 79.42% | Total | 72.06% |
| No. | Product | $\frac{0}{0}$ | 2015 Sales (NT\$) |
|---|---|---|---|
| 1 | HOCLQ Sulfate | 20.09% | 257,350,210 |
| $\overline{2}$ | PGA | 14.67% | 187,934,647 |
| 3 | V.A. | 10.18% | 130,440,736 |
| $\overline{\mathbf{4}}$ | LPF.Na | 8.99% | 115, 114, 448 |
| $5\overline{)}$ | Di-VaNa | 6.84% | 87,611,577 |
| 6 | S2038 | 5.46% | 69,935,362 |
| $\overline{\mathbf{7}}$ | DBS | 3.69% | 47,321,924 |
| 8 | Pent-2 | 3.16% | 40,472,440 |
| 9 | 5-HMT | 3.07% | 39,320,470 |
| 10 | NaVA | 2.03% | 26,035,132 |
SCI
-
Hydroxychloroquine sulfate
-
2015sales: 257M
風濕性關節炎藥物 For rheumatoid arthritis 7個客戶 8 customers
Pyrogallolaldehyde ( PGA) - Benserazide
治療帕金森氏症之中間體 Intermediate for Parkinson's Disease
2個客戶 2 customer
2015 sales: 188M
Anti-inflammatory (Loxoprofen sodium)
日本市場200-300公噸 Japan market:200-300MT 2015 sales: 115M
S20/38
臨床藥物 Medication in clinical trial 2015 sales: 70M
Valproic Acid (VA)
20個客戶 20 customers 2015 sales: 130M
產品介紹Product
Divalproex Sodium (Di-Va)
學名藥於2009推出 Generic came out in 2009 10個客戶 10 customers 2015 sales: 88M
產品介紹Product
Pentobarbital Sodium (鎮定安眠用, calmative)
2015 sales:19M
Pent-2
Antidepressant (Duloxetine) 2013年底專利到期 Patent expired in the end of 2013 2014 sales: 12 M 2015 sales: 18M
Antidepressant (S-MMAA) Duloxetine之中間體 intermediate of Duloxetine 2014 sales: 27 M 2015 sales: 22 M
Sodium Valproate (NaVA)
24 客戶 24 customers 2015 sales: 26M
愛滋病藥物中間體 For AIDS treatment 2015 sales: 39M
GMP Status(GMP現況)
| API | CGMP certified |
CEP (EDQM) |
DMF (USA) |
MF (Japan) |
DMF (Canada) |
|---|---|---|---|---|---|
| (TFDA) | |||||
| Valproic Acid (*) |
2003 | 2004 | 2003 | 2008 | 2008 |
| Allopurinol | 2004 | 2003 | 2011 | ||
| Probucol | 2004 | 2004 | |||
| Sodium Valproate |
2004 | 2006 | |||
| Divalproex Sodium (**) |
2005 | 2005 | 2010 | ||
| Bisoprolol Fumarate |
2006 | ||||
| Pentobarbital Sodium |
2009 | 2 011 |
|||
| Propafenone Hydrochloride |
2010 | 2012 | 2010 | 2012 | 2012 |
| Methylphenidate HCl |
2 011 |
2014 | |||
| Duloxetine Hydrochloride |
2012 | 2014 | 2010/2011 | ||
| Thiopental acid |
2012 | ||||
| Loxoprofen Sodium Hydrate |
2012 | 2011 | |||
| Articaine Hydrochloride |
2013 | 2014 | 2014 | ||
| Hydroxychloroquine Sulfate |
2014 | 2014 | 2014 | ||
| Clindamycin Palmitate HCl |
2011 | ||||
| Cyclophosphamide | 2014 | 2012 |
(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010
